

# Monthly Market Commentary

July was a good month for global equities, particularly US large capitalisation stocks which set record highs. A generally good start to reporting season helped. Additionally, greater clarity on US tariffs, and the passing of the 'One Big Beautiful Bill Act' buoyed risk-on sentiment.

Investors appeared unconcerned that US consumers are facing the highest tariff regime since the 1930s at the same time as US government finances are set to become even more stretched. According to the Congressional Budget Office, the US federal deficit is expected to remain at an elevated level of around 6% of GDP over the next decade. Over the same period, the July enacted 'One Big Beautiful Bill' is estimated to add approximately USD\$4.1 trillion to the deficit, potentially pushing it to over 7% of GDP.

As noted, US markets were strong in July with the NASDAQ and S&P500 up 3.7% and 2.17%, respectively. In contrast, small caps lagged with the S&P600 Small Cap Index up only 0.9%. In local currency terms, overseas bourses also did well with the UK FTSE up 4.2%, well ahead of France's CAC and Germany's DAX which rose 1.4% and 0.7%, respectively. In Asia, China's Shanghai Composite Index was up 3.7%, with Japan's Nikkei225 also up 1.4%. Given broad-based US optimism and the accompanying strength of the USD in July (DXY Index +3.1%), overseas bourse returns were lower in USD terms.

Information Technology was the standout performer on a sector basis, up 4.1%, with Energy and Utilities also delivering solid performance, up 2.4% and 2.2%, respectively. At the other end of the spectrum, Health Care fell 3.1% thanks to more weakness in US managed care stocks (further downgrades thanks to rising medical costs) and significant share price falls in some high profile GLP-1 makers. Most notably, Novo Nordisk's share price fell ~23% after downgrading FY25 EBIT growth to 10-16% (vs previous guidance of 16-24% growth) - a reminder that investors can still lose money even as profits grow.

Against this backdrop the Fund returned +0.21% for the month.

The Australian dollar fell 2.4% against the USD in July. Commodities were modestly lower with the Bloomberg Commodity Index down 0.8%, despite a 6.4% rise in WTI oil prices. VIX remained largely unchanged during the month at around 16.7, with yields on US 10yr Treasuries rising 15bps to close at 4.37%.

Pharmaceutical giant, Johnson & Johnson was the biggest contributor to Fund performance in July, bucking the broader trend in Health Care weakness. Its shares rose strongly after a solid Q2 result where the company raised FY25 sales and EPS guidance and signalled positive momentum into 2026 with potential upside to long-term targets. With the stock trading on a ~15x P/E, it still offers compelling value, and we will continue holding.

Goldminer Newmont was also a meaningful contributor to the Fund's performance. Its shares rose after a strong Q2 result characterised by good cost management, conservative FY25 production guidance and more cash returns to shareholders via a new USD\$3bn buyback. Having divested most non-core assets, Newmont now owns some of the most attractive gold mines globally (longest-life/lowest-cost). It also enjoys considerable balance sheet optionality (Net Debt/EBITDA ~0.1x) meaning it can still fund even more capital management initiatives. Hence, with the stock trading on a ~8% FCF yield (based on spot gold prices) there remains significant upside for shareholders from here.

Swedish health and hygiene group, Essity was the Fund's biggest detractor. The shares fell after it missed Q2 earnings estimates by ~5% thanks to weaker-than-expected volumes, FX headwinds and higher cost of goods sold. The company also flagged higher investments as it looks to re-ignite volume growth. The good news is that a solid balance sheet affords management time to execute an uptick in volumes, and with the stock trading near-trough sales multiples we think the skew is to the upside (~30% upside to where we see fair value).

We believe the most compelling way to compound clients' wealth is by utilising multiple return sources to deliver superior risk-adjusted investment outcomes.

- Long-term compounding of investor wealth
- Multiple sources of return
- Quarterly distributions
- Risk focused investment mindset



The investment process behind the Talaria Global Equity Fund Currency Hedged Complex ETF takes a high conviction, value biased approach to construct a portfolio of high quality, large cap companies from around the globe. Our unique investment methodology harnesses the benefits of consistent income generation and capital appreciation to grow investors' real wealth.


## Performance as at 31 July 2025<sup>1</sup>

	1 Month	3 Months	6 Months	1 Year	3 Years (pa)	5 Years (pa)	7 Years (pa)	10 Years (pa)	Since Inception (pa) <sup>2</sup>
Total Return	0.21%	1.51%	-0.12%	2.22%	6.72%	10.03%	6.50%	6.07%	7.23%
Avg. Market Exposure <sup>4</sup>	58%	58%	61%	64%	59%	58%	58%	59%	59%

<sup>1</sup> Fund Returns are calculated after fees and expenses and assume the reinvestment of distributions.  
<sup>2</sup> Inception date for performance calculation is 31 December 2012.  
<sup>3</sup> Past performance is not a reliable indicator of future performance.


<sup>4</sup> Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio. Since inception market exposure is calculated from 31 December 2012.

## Growth of \$10,000 Since Inception<sup>5</sup>



<sup>5</sup> Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions Past performance is not a reliable indicator of future performance.

## Annual Distributions<sup>6</sup>




<sup>6</sup> Illustrates Distribution Returns for the Talaria Global Equity Fund Currency Hedged Complex ETF Units for the financial year ending 30 June 2025. Inception date is 31 December 2012.

Top 10 Holdings<sup>7</sup>

Company Name	Holding	Country	Sector	Description
Newmont	5.5%	USA	Materials	One of the top 3 gold producers in the world
Roche	4.8%	Switzerland	Health Care	A global leader in cancer treatments
Sanofi	4.7%	France	Health Care	Top 5 pharmaceutical firm with leading positions in diabetes and rare diseases
Everest Re	4.5%	USA	Financials	Leading global provider of reinsurance and insurance services
Johnson & Johnson	4.2%	USA	Health Care	Pharmaceutical, medical devices and consumer health products company
Essity	3.6%	Sweden	Consumer Staples	A global health and hygiene company based in Sweden
Bunzl	3.5%	United Kingdom	Industrials	Multinational distribution and outsourcing business
Chubb	3.5%	USA	Financials	Global Property & casualty insurance company
Bayer	3.4%	Germany	Health Care	Multinational pharmaceutical and life sciences company
CF Industries	3.2%	USA	Materials	North America's largest manufacturer of nitrogen-based fertiliser


7 Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Sector Allocation<sup>8</sup>



8,9 Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Regional Allocation<sup>9</sup>



\* USA includes American Depositary Receipts (ADRs) listings.

Fund Snapshot

APIR Code	WFS0547AU	Inception Date	31 December 2012
Management Fee	1.20% p.a. of the net asset value of the Fund plus Recoverable Expenses	Liquidity	Daily
Recoverable Expenses	Estimated to be 0.12% of net asset value of the Fund each Financial Year	Exit Price	\$5.51250 (31 Jul 2025)
		Buy / Sell Spread	0.25% / 0.25%
Major Platform Availability	Asgard, Ausmaq, BT Panorama, BT Wrap, CFS Edge, CFS FirstChoice, Dash, Expand, Hub24, IconiQ, IOOF Pursuit, Linear, Macquarie, Mason Stevens, Netwealth, North, Powerwrap, Praemium	Distributions	Quarterly
		Minimum Investment	\$5,000

Important Information

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975 is the Responsible Entity for the Talaria Global Equity Fund Currency Hedged Complex ETF ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). This report has been prepared by Talaria Asset Management ("Talaria") to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Talaria, Equity Trustees nor any of its related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. Talaria Global Equity Fund Currency Hedged Complex ETF's Target Market Determination is available [here](#). A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed. The Zenith Investment Partners (ABN 27 103 152 672, AFSL Licence 226872) ("Zenith") rating (assigned November 2024 for fund AUS0035AU) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2007) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines. The rating issued 04/2025 is published by Lionsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lionsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lionsec assumes no obligation to update Lionsec uses objective criteria and receives a fee from the Fund Manager. Visit [lionsec.com.au](#) for ratings information and to access the full report. © 2025 Lionsec. All rights reserved. The Zenium rating (assigned May 2025) presented in this document is issued by Zenium Investment Partners Pty Ltd ABN 13 165 099 785, which is a Corporate Authorised Representative of Zenium Advisory Services Pty Ltd ABN 94 304 403 582, AFSL 246580. The Rating is limited to "General Advice" (s766B Corporations Act 2001 (Ch)) and has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without notice. Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision in relation to this financial product(s). Zenium receives a fee from the Fund Manager for researching and rating the product(s). Visit [Zeniumip.com.au](#) for information regarding Zenium's Ratings methodology. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by Talaria Asset Management. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

